Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge.

Nicholas PiccicaccoKristen ZeitlerAustin IngJose MonteroJonathan FaughnSuzane SilbertKami Kim

Published in: The Journal of antimicrobial chemotherapy (2022)

Our highest-risk outpatients with Omicron-related COVID-19 who received early sotrovimab or remdesivir had significantly lower likelihoods of a hospitalization and/or ED visit.

Keyphrases

coronavirus disease
sars cov
emergency department
systematic review
respiratory syndrome coronavirus